# Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO

> **NCT06276010** · NA · RECRUITING · sponsor: **Xiaotong Hou** · enrollment: 80 (estimated)

## Conditions studied

- Extracorporeal Membrane Oxygenation Complication

## Interventions

- **DRUG:** nafamostat mesilate
- **DRUG:** unfractionated heparin group

## Key facts

- **NCT ID:** NCT06276010
- **Lead sponsor:** Xiaotong Hou
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2026-11-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06276010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06276010, "Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06276010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*